<DOC>
	<DOCNO>NCT00536939</DOCNO>
	<brief_summary>The purpose study determine efficacy safety paclitaxel , bevacizumab enzastaurin versus paclitaxel , bevacizumab , placebo patient diagnose locally recurrent metastatic breast cancer .</brief_summary>
	<brief_title>Trial Paclitaxel , Bevacizumab , Enzastaurin Versus Paclitaxel , Bevacizumab Placebo Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Must sign inform consent document Have histologic cytologic diagnosis breast cancer evidence unresectable locally recurrent metastatic disease Have receive prior chemotherapy locally recurrent metastatic disease Have adjuvant neoadjuvant taxane therapy within 12 month prior assignment study treatment Age 18 year old time inform consent Have clinical evidence central nervous system ( CNS ) metastasis Have history seizure Have major surgical procedure within 4 week prior assignment study treatment Have minor surgical procedure , placement access device , fine needle aspiration within 7 day prior assignment study treatment Have symptomatic peripheral vascular disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2009</verification_date>
</DOC>